Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
13 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CABINET DU DR MARIE-PIERRE LANG
56 RUE DE VOUILLE, 75015 PARIS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
British journal of sports medicine · 2020
ObjectivePhysical activity (PA) has substantial benefits across a range of health outcomes. There is uncertainty about the PA-specific health effects, and in particular, the occupational domain. In this umbrella review, we synthesised available evidence on the associations between occupational PA (OPA) and health-related outcomes (including cancer, all-cause mortality and cardiovascular disease). This work informed the development of WHO’s guidelines on PA and sedentary behaviour (2020).DesignUmbrella review of systematic reviews.Data sourceWe performed a literature search in PubMed, Web of Science, Embase, CINAHL and Sportdiscuss from database inception to 2 December 2019.Eligibility criteria for selecting studiesWe included systematic reviews if they contained a quantitative assessment of OPA and its relationship with at least one health-related outcome.ResultsWe summarised the evidence of 17 reviews covering 23 unique health-related outcomes. We graded most evidence as low or very low, or moderate quality. We found health benefits for those engaging in high versus low OPA for multiple cancer outcomes (including colon and prostate), ischaemic stroke, coronary heart disease and mental health (ie, mental well-being and life satisfaction). High OPA was associated with unfavourable health outcomes for all-cause mortality in men, mental ill health (ie, depression and anxiety), osteoarthritis, and sleep quality and duration.ConclusionsWe found favourable associations for most health-related outcomes with high OPA levels, but we also found some evidence for unfavourable associations due to high OPA levels. At this point, there is a need for better quality evidence to provide a unequivocal statement on the health effects of OPA.
Immunobiology · 1985
Thrombosis and haemostasis · 2016
SummaryNon-vitamin K antagonist oral anticoagulants (NOAC), including rivaroxaban, apixaban or dabigatran, regularly show relevant effects on coagulation tests, making the interpretation of results difficult. The aim of this study was to evaluate possible interferences of NOACs in trough level concentrations in lupus anticoagulant (LA) testing. Citrate plasma specimens of 30 healthy volunteers were spiked with rivaroxaban, apixaban or dabigatran in four plasma concentration levels at or below trough NOAC levels. The NOAC concentration was measured using dedicated surrogate concentration tests and a stepwise diagnostic procedure for LA-testing was applied using screening, mixing and confirmatory testing. Results were compared to NOAC-free specimens. Starting with a plasma concentration of 12.5 ng/ml, dabigatran-spiked specimens showed significant prolongations in the lupus anticoagulant-sensitive activated partial thromboplastin time (aPTT-LA) as well as in the Dilute Russell viper venom time (dRVVT), leading to 43.3% false positives in confirmatory testing in the dRVVT. In contrast, rivaroxaban, beginning with 7.5 ng/ml, exclusively affected dRVVT-based tests. In confirmatory tests, 30.0% of rivaroxaban-spiked specimens showed false positive results. Starting with 18.75 ng/ml apixaban, a significant prolongation of the dRVVT and up to 20.7% false positives in confirmatory tests were found. In contrast to other NOACs tested, apixaban did not present with a dose-dependent increase of the dRVVT ratio. In conclusion, the rate of false positive results in LA-testing is unacceptably high at expected trough levels of NOACs. Even at plasma concentrations below the LLOQ of commercially available surrogate tests, LA testing is best avoided in patients with NOAC therapy.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Archives of pathology & laboratory medicine · 2018 · Journal Article
Ratzinger F, Lang M, Belik S, Schmetterer KG, et al.
British journal of hospital medicine (London, England : 2005) · 2017 · Case Reports
Lang M, Fish J, Covelli C, Schreiber BE
Thrombosis and haemostasis · 2016 · Journal Article
Ratzinger F, Lang M, Belik S, Jilma-Stohlawetz P, et al.
Transplantation proceedings · 1995 · Clinical Trial
Neuhaus R, Lohmann R, Platz KP, Guckelberger O, et al.
Aktuelle Traumatologie · 1994 · Journal Article
Jockheck M, Lang M, Weller S
Frontiers in immunology · 2023 · Journal Article
Lang MB, Leung KY, Greene NDE, Malone KM, et al.
Lupus · 2022 · Journal Article
Lang MG, Vinagre CG, Bonfa E, Freitas FR, et al.
British journal of rheumatology · 1988 · Journal Article
Weiss EH, Bloemer K, Doerner C, Kuon W, et al.
Immunobiology · 1985 · Journal Article
Weiss EH, Kuon W, Dörner C, Lang M, et al.
Annals of hematology · 2026 · Journal Article
Lang M, Peng L, Jiang N, Li M, et al.
Lupus · 2022 · Journal Article
Lang MG, Vinagre CG, Bonfa E, Freitas FR, et al.
Journal of experimental orthopaedics · 2021 · Journal Article
Turner EHG, Lang MDH, Spiker AM
British journal of sports medicine · 2020 · Journal Article
Cillekens B, Lang M, van Mechelen W, Verhagen E, et al.
British journal of sports medicine · 2020 · Journal Article
Cillekens B, Lang M, van Mechelen W, Verhagen E, et al.
BMC women's health · 2016 · Journal Article
Bilek LD, Waltman NL, Lappe JM, Kupzyk KA, et al.